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compared to single MCI cases, significant differences
included: female gender (P< .0349), receipt of allo-HSCT (P<
.0373), vancomycin (P< .0012) and cefepime (P < .0009) use.
There was no difference in the number of patients who
experienced neutropenic fever between MMCI, MCI (P <
.275) or culture negative cases (P < .1247). Strept mitis or
C.difficileinfection occurred concommitantly or preceded the
second MCI in 29(47%) cases. Overall mortality was signifi-
cantly higher in MMCI cases when compared to cases
without any positive cultures (P < .001) or patients with
a single MCI (P < .0197). There was no difference in overall
mortality for patients who developed MMCI <72hours
(polymicrobial) versus MMCI>72 (non-polymicrobial; P <
.2990).
MMCI are an infrequent but serious cause of adverse events
which occur during HSCT. Patients who are at high risk for
developing MMCI require increased vigilance and early
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Background: In 2004, the National Marrow Donor Pro-
gram's database merged with the International Bone
Marrow Transplant Registry to streamline transplant
research. To manage the fusion of forms generated in two
separate databases, the Center for International Blood and
Marrow Transplant Research (CIBMTR) began assigning
each patient a unique Recipient Identification Number
(CRID) in 2007. This has allowed transplant outcomes to be
reported annually, because forms are now automatically
generated for each CRID. Our center created a secure CRID
spreadsheet to manage the merge and track form due dates
(Figure 1). The spreadsheet has evolved into an auditing
tool, serving to simplify our form assignment process and
improve quality.
Best Practices: Using Forms Net, a designated Protocol
Coordinator (PC) generates a monthly list of forms due for
the next five week reporting period. Next, the list is exported
to an excel spreadsheet allowing the PC to assign forms to
Data Coordinators (DC's) with a DC due date set two weeks
prior to the final due date in FormsNet. After the forms are
assigned, DC's use the CRID spreadsheet to cross reference
CRID numbers with Medical Record Numbers (MRN) to
identify the corresponding patient to complete forms. The PC
reviews each form using the CRID spreadsheet to track any
errors made by the DC completing the form. Next, the
audited forms are returned to the DC who corrects and
reprocess the form in FormsNet. Each quarter, a designated
DC cross references the CRID spreadsheet with Forms Net to
ensure error correction and data quality. The spreadsheet can
also be used as an opportunity to re-educate DC's on
frequently missed fields and reduce errors on the following
month's forms.Outcomes: In the 2008 CIBMTR audit, our center's critical
field error rate was 4.2%. Subsequently, implementation of
the secure CRID spreadsheet helped reduce our 2012 critical
field error rate to 1.7%. This tool will continue increasing
data quality and reporting outcomes while concomitantly
helping us reach our department goal of <1% error rate in
2016.
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Introduction: Each hematopoietic stem cell transplant
(HSCT) performed and fully reported to CIBMTR generates
key information to support research that has cumulatively
led to increased survival and enriched quality of life of
thousands of patients. Between 50 and 60 HSCT (autolo-
gous, related and unrelated) are now annually performed
at the Pediatric Oncology Institute, São Paulo, Brazil. The
program started in 1999 and the first 167 transplants
were reported by physicians and by the Cell Processing
Laboratory staff. However, over the past 4 years, the
institution was unable to keep up with the reporting
schedule due to increasing working load. In February
2012, the effort to report all new and old patients to
CIBMTR was resumed.
Objective: To report and share the strategy used to have all
629 forms efficiently updated and reported within 8
months.
Methods: The institutional efforts started by hiring
a trained CRA part time devoted to CIBMTR data manage-
ment. A very useful and comprehensive Excel-based
spreadsheet was developed to have visual display of all due
dates with colorful flags and automatic updates to the
current date. Work flows were developed to capture data
during weekly medical rounds. All sources of medical
information e charts, laboratory and radiological reports,
medical round reports - were accessed whenever necessary
and included in the patient charts as documented source of
information. All forms were weekly reviewed with a senior
physician to ensure appropriate training and education of
the new CRA.
Results: A total of 360 patients underwent HSCT between
1999 and September 2012. The CIBMTR forms had been
last updated in 2008 and no new patients were registered
since then. All information that posed the greatest
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were included in the new work flow. A list of disease-
specific staging was developed to guide disease status at
annual evaluations. A visual approach was created in the
spreadsheet to track forms completion with all patients
due dates as follows: green - form may be completed, red
- time to complete form has not yet been reached, blue -
form is ready to be reported, yellow - form must be
reviewed, purple - patient underwent another HSCT and
black - death.
Conclusion: In October 2012 our goal was achieved and we
were able to update and report all 193 patients. Team work
and new efficient tools allowed control of due dates and
optimization of time spent with data capturing, CRA/physi-
cian meetings and forms review. All items from all patients
will now be timely reported.326
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Background: The DFCI/BWCC HSCT program is estimated
to perform 525 transplants in 2012, and has performed
6000 transplants since inception in 1972. The quality
of this data had previously not been reviewed on a large
scale, only by smaller projects examining selected data
fields for limited patient sets. The accuracy of this data
is paramount since it is used for analysis of patient
outcomes, policy compliance and operational
considerations.
The goal of this project was to develop a comprehensive
and efficient method of data validation for DFCI's internal
HSCT repository and DFCI's SCTOD data.
Methods: Fifty-nine transplant essential data fields were
selected for analysis including Day 0, Disease Status at
Transplant, Best Response, aGVHD, and cGVHD. A program
for comparing DFCI's internal repository data and DFCI's
CIBMTR data (retrieved with the Data Back to Center tool)
was designed in Microsoft Access, accounting for slight
differences in coding rules and logic. In 2011 over 200,000
individual data points were compared. The analysis was
performed in 2012 with more recent data.
Results: In 2011 the pre-HSCT and post-HSCT data sets
had overall error rates of 0.51% and 0.77%, respectively.
The pre-HSCT fields with error rates above 2% were
Diagnosis Date (2.16%), KPS (2.23%), and Reason RIC
(2.22%). The post-HSCT fields with high error rates above
2% were Cause of Death (3.27%) and Date of Death (3.94%).
All errors were corrected and areas for staff education
and codebook improvements were determined and
implemented.
In 2012 the error rates for the previous year's fields with
high error rates were Diagnosis Date (3.71%), KPS (0.80%),
Reason RIC (2.14%), Cause of Death (2.34%), and Date of Death
(1.37%) for data reported before the educational updates. The
coding accuracy improved for data reported after the
educational updates. For example, the error rates for the data
that was reported after the educational updates for the
previous year's fields with high error rates were Diagnosis
Date (0.70%), KPS (1.69%), and Reason RIC (1.67%). Very
limited post-HSCT data was available for data reported after
the educational updates.Conclusion: The pre-HSCT and post-HSCT data sets for
DFCI's internally and externally reported data had overall
percent error rates well below the HSCT Program's target
error rate of 2% or lower. When the analysis was performed
after staff education and codebook revisions, data accuracy
improved. Comparing similar data entered into different
databases is a valuable tool to correct data errors, as well as
to improve data accuracy in the future.328
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Cancer Registrars Evolving in Bone Marrow Transplant Data
Management Christine Gibson, CTR, CCRP Cancer Registrars
are well versed in the language of Cancer. CTR credentials are
given once education, training and testing is satisfied.
Training includes, anatomy and physiology, AJCC staging,
NAACCR (The North American Association of Central Cancer
Registries) guidelines for data capture, CDC, NCI SEER
guidelines for Hematopoietic Database, Collaborative
Staging, NCCN treatment guidelines and Commission on
Cancer guidelines. Many resources and many regulatory
bodies over see the data as we over see the data in our own
institutions. Standards of Care and comparisons are made to
assure the best possible patient experience. Diagnosis
information, pathology, molecular testing, IHC, FISH; cyto-
genetic, tumor markers and prognostic indicators are the
foundation of caner reporting. Radiology tests and surgical
interventions with histological diagnosis, dictate the stage of
cancer. Once a stage of cancer is derived; a treatment plan
can be made. Cancer treatment is captured in the cancer
registry. Chemotherapy regimens, radiation, immuno-
therapy, vaccines and bonemarrow transplant information is
abstracted into the cancer registry. Cancer Programs that are
American College of Surgeons, Commission on Cancer
approved are required to have Cancer Registries. Annual
follow up compliance is mandatory for all cancer patients in
the cancer registry. It would seem that if resources were
shared between the registries and regulators it could be
more cost effective, and provide better data capture for the
hematopoietic diseases. While many similarities exist
between the two entities there are many differences.
Continuous education is mandatory in a research environ-
ment. I have expanded my knowledge base. I have since
learned about consents, regulatory agencies, engraftment,
chimerism, acute and chronic GVHD, toxicities, infections
and the many different time lines to report. Cancer registry
background helped tremendously and working in a world
class facility with world class physicians made the transition
much easier.329
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